531 related articles for article (PubMed ID: 24782555)
21. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA
J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407
[TBL] [Abstract][Full Text] [Related]
22. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis.
Van Meter DJ; Corriveau M; Ahern JW; Lahiri T
Pediatr Pulmonol; 2009 Apr; 44(4):325-9. PubMed ID: 19330772
[TBL] [Abstract][Full Text] [Related]
23. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
24. Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients.
Koo J; Tight R; Rajkumar V; Hawa Z
Am J Med; 1996 Aug; 101(2):177-83. PubMed ID: 8757358
[TBL] [Abstract][Full Text] [Related]
25. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.
Stenbit AE; Bullington WM; Heh JL; Flume PA
J Cyst Fibros; 2013 Jul; 12(4):403-6. PubMed ID: 23266092
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
Brigg Turner R; Elbarbry F; Biondo L
J Chemother; 2016 Aug; 28(4):304-7. PubMed ID: 26430825
[TBL] [Abstract][Full Text] [Related]
27. Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis.
Nestaas E; Bangstad HJ; Sandvik L; Wathne KO
Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F294-300. PubMed ID: 15857879
[TBL] [Abstract][Full Text] [Related]
28. Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.
Garinis A; Gleser M; Johns A; Larsen E; Vachhani J
J Cyst Fibros; 2021 Mar; 20(2):278-283. PubMed ID: 32713806
[TBL] [Abstract][Full Text] [Related]
29. Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand.
Larcombe R; Coulthard K; Eaton V; Tai A; Reuter S; Ward M
Eur J Hosp Pharm; 2024 Jun; 31(4):301-306. PubMed ID: 36600520
[TBL] [Abstract][Full Text] [Related]
30. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.
Aminimanizani A; Beringer PM; Kang J; Tsang L; Jelliffe RW; Shapiro BJ
J Antimicrob Chemother; 2002 Oct; 50(4):553-9. PubMed ID: 12356801
[TBL] [Abstract][Full Text] [Related]
31. Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections.
Paradisi F; Corti G
J Chemother; 1995 Aug; 7(4):338-43. PubMed ID: 8568544
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic drug monitoring of aminoglycosides in acute myeloid leukaemia patients.
Mareville J; Gay J; Cliquennois E; Herbaux C; Pasquier F; Allorge D; Blondiaux N; Berthon C; Alfandari S
Scand J Infect Dis; 2012 May; 44(5):398-401. PubMed ID: 22235869
[TBL] [Abstract][Full Text] [Related]
33. Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis.
Rohani R; Hoff B; Jain M; Philbrick A; Salama S; Cullina JF; Rhodes NJ
Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):199-209. PubMed ID: 34882292
[TBL] [Abstract][Full Text] [Related]
34. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.
Freeman CD; Nicolau DP; Belliveau PP; Nightingale CH
J Antimicrob Chemother; 1997 Jun; 39(6):677-86. PubMed ID: 9222035
[TBL] [Abstract][Full Text] [Related]
35. Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population.
Albright JC; Houck AP; Pettit RS
Pediatr Pulmonol; 2020 Oct; 55(10):2662-2666. PubMed ID: 32568427
[TBL] [Abstract][Full Text] [Related]
36. "Once-daily" versus "extended-interval" administration of aminoglycosides in neonates: need for standard terminology.
Miller MM; Burton ME; Johnson PN; Miller JL
Am J Health Syst Pharm; 2014 Dec; 71(24):2108-9. PubMed ID: 25465576
[No Abstract] [Full Text] [Related]
37. Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis?
van Maarseveen EM; van der Meer R; Neef C; Heijerman HGM; Touw DJ
Ther Drug Monit; 2020 Aug; 42(4):595-599. PubMed ID: 32049889
[TBL] [Abstract][Full Text] [Related]
38. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
[TBL] [Abstract][Full Text] [Related]
39. [Use of aminoglycosides in Danish intensive care units].
Thorvaldsen M; Christrup LL; Bonde J
Ugeskr Laeger; 2004 May; 166(23):2246-50. PubMed ID: 15487522
[No Abstract] [Full Text] [Related]
40. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
